Bayer AG (XTER:BAYN) Dividends Received


XTER:BAYN Bayer AG XTER:BAYN
56 GF Score
Price €50.82
GF Value €27.39
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Bayer AG Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

XTER:BAYN
56GF Score
Bayer AG XTER:BAYN
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bayer AG (XTER:BAYN) Overvalued in 2026?

Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued. The current stock price of €50.82 is trading 85.5% above its estimated GF Value™ of €27.39. GuruFocus considers Bayer AG to be Significantly Overvalued.

Key valuation signals for XTER:BAYN:

  • Dividends Received:
  • GF Value™: €27.39 vs. price of €50.82 (85.5% above fair value)
  • GF Score™: 56/100 with 7 warning signs

No single metric tells the full story. See the XTER:BAYN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bayer AG Business Description

Address Kaiser-Wilhelm-Allee 1, Leverkusen, NW, DEU, 51368
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
56GF Score

Get the complete analysis for XTER:BAYN

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€50.82
Price
€27.39
GF Value